BR112014009053B1 - Compostos indutores de apoptose, uso dos mesmos para o tratamento de determinados tipos de câncer e composição farmacêutica que compreende os ditos compostos - Google Patents
Compostos indutores de apoptose, uso dos mesmos para o tratamento de determinados tipos de câncer e composição farmacêutica que compreende os ditos compostos Download PDFInfo
- Publication number
- BR112014009053B1 BR112014009053B1 BR112014009053-0A BR112014009053A BR112014009053B1 BR 112014009053 B1 BR112014009053 B1 BR 112014009053B1 BR 112014009053 A BR112014009053 A BR 112014009053A BR 112014009053 B1 BR112014009053 B1 BR 112014009053B1
- Authority
- BR
- Brazil
- Prior art keywords
- methyl
- dec
- ylcarbamoyl
- benzothiazol
- dihydroisoquinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547162P | 2011-10-14 | 2011-10-14 | |
| US61/547,162 | 2011-10-14 | ||
| CNPCT/CN2012/079012 | 2012-07-23 | ||
| CN2012079012 | 2012-07-23 | ||
| PCT/US2012/059720 WO2013055897A1 (en) | 2011-10-14 | 2012-10-11 | 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014009053A2 BR112014009053A2 (pt) | 2017-06-13 |
| BR112014009053B1 true BR112014009053B1 (pt) | 2022-03-29 |
Family
ID=47116421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014009053-0A BR112014009053B1 (pt) | 2011-10-14 | 2012-10-11 | Compostos indutores de apoptose, uso dos mesmos para o tratamento de determinados tipos de câncer e composição farmacêutica que compreende os ditos compostos |
Country Status (36)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI561521B (en) | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2016094505A1 (en) * | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
| MX2017007629A (es) * | 2014-12-09 | 2018-05-17 | Abbvie Inc | Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen. |
| BR112017012342A2 (pt) * | 2014-12-09 | 2018-02-27 | Abbvie Inc | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos |
| CN104473923B (zh) * | 2014-12-29 | 2016-08-17 | 巩春智 | 一种防治慢性心力衰竭的药物组合物及其应用 |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| JP2019522643A (ja) * | 2016-06-08 | 2019-08-15 | アッヴィ・インコーポレイテッド | 抗ｃｄ９８抗体及び抗体薬物コンジュゲート |
| IL300274A (en) * | 2016-06-08 | 2023-04-01 | Abbvie Inc | Antibodies against B7–H3 and conjugates of drug and antibody |
| EP3468598A1 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| WO2017214462A2 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| RU2018147224A (ru) * | 2016-06-08 | 2020-07-14 | Эббви Инк. | Конъюгаты антитела к egfr и лекарственного средства |
| JP2019521114A (ja) * | 2016-06-08 | 2019-07-25 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート |
| BR112018075645A2 (pt) * | 2016-06-08 | 2019-04-09 | Abbvie Inc. | conjugados de anticorpo fármaco anti-egfr |
| WO2018092064A1 (en) * | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
| WO2019000236A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| TW202002952A (zh) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療胰臟癌之abbv-621與抗癌劑之組合 |
| AR119494A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS |
| IL303048A (en) | 2020-11-24 | 2023-07-01 | Novartis Ag | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| KR20230170644A (ko) | 2021-02-02 | 2023-12-19 | 르 라보레또레 쎄르비에르 | 선택적 bcl-xl protac 화합물 및 사용 방법 |
| JP2025516359A (ja) * | 2022-05-06 | 2025-05-27 | ツリーライン バイオサイエンシズ インコーポレイテッド | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 |
| IL316465A (en) * | 2022-05-06 | 2024-12-01 | Treeline Biosciences Inc | BCL-XL tetrahydroisoquinoline heterobifunctional compounds |
| US20250339547A1 (en) | 2022-05-20 | 2025-11-06 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CR20240553A (es) | 2022-05-20 | 2025-05-02 | Servier Lab | Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos |
| WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| EP4538273A1 (en) * | 2022-06-10 | 2025-04-16 | Hitgen Inc. | Compound and use thereof in preparation of bcl-xl inhibitor |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| KR100526487B1 (ko) * | 2000-06-21 | 2005-11-08 | 에프. 호프만-라 로슈 아게 | 벤조티아졸 유도체 |
| WO2004058266A1 (en) | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
| DE602004020812D1 (de) | 2004-07-20 | 2009-06-04 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| EP2121641B1 (en) | 2007-02-15 | 2014-09-24 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands |
| US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090131363A1 (en) | 2007-10-26 | 2009-05-21 | Harbeson Scott L | Deuterated darunavir |
| AU2009335843A1 (en) * | 2008-12-19 | 2011-07-21 | Abbvie Inc. | Heterocyclic compounds and methods of use |
| PE20120305A1 (es) * | 2008-12-19 | 2012-04-09 | Abbott Lab | Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl |
| KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2012
- 2012-10-08 TW TW101137131A patent/TWI571466B/zh not_active IP Right Cessation
- 2012-10-10 UY UY0001034382A patent/UY34382A/es unknown
- 2012-10-11 RS RS20160954A patent/RS55342B1/sr unknown
- 2012-10-11 DK DK12780605.7T patent/DK2766361T3/en active
- 2012-10-11 LT LTEP12780605.7T patent/LT2766361T/lt unknown
- 2012-10-11 KR KR1020147012846A patent/KR102019643B1/ko not_active Expired - Fee Related
- 2012-10-11 SG SG11201401279XA patent/SG11201401279XA/en unknown
- 2012-10-11 HR HRP20161319TT patent/HRP20161319T1/hr unknown
- 2012-10-11 PE PE2014000506A patent/PE20141282A1/es active IP Right Grant
- 2012-10-11 HU HUE12780605A patent/HUE030589T2/en unknown
- 2012-10-11 AU AU2012322698A patent/AU2012322698A1/en not_active Abandoned
- 2012-10-11 CA CA2851364A patent/CA2851364C/en active Active
- 2012-10-11 BR BR112014009053-0A patent/BR112014009053B1/pt not_active IP Right Cessation
- 2012-10-11 UA UAA201405089A patent/UA115042C2/uk unknown
- 2012-10-11 ME MEP-2016-227A patent/ME02514B/me unknown
- 2012-10-11 RU RU2014119250A patent/RU2625315C2/ru active
- 2012-10-11 PT PT127806057T patent/PT2766361T/pt unknown
- 2012-10-11 WO PCT/US2012/059720 patent/WO2013055897A1/en not_active Ceased
- 2012-10-11 PH PH1/2014/500729A patent/PH12014500729A1/en unknown
- 2012-10-11 ES ES12780605.7T patent/ES2598877T3/es active Active
- 2012-10-11 JP JP2014535869A patent/JP6155270B2/ja active Active
- 2012-10-11 SI SI201230730A patent/SI2766361T1/sl unknown
- 2012-10-11 MY MYPI2014700867A patent/MY172723A/en unknown
- 2012-10-11 CR CR20200097A patent/CR20200097A/es unknown
- 2012-10-11 EP EP12780605.7A patent/EP2766361B1/en active Active
- 2012-10-11 PL PL12780605T patent/PL2766361T3/pl unknown
- 2012-10-11 MX MX2014004556A patent/MX356031B/es active IP Right Grant
- 2012-10-12 AR ARP120103811A patent/AR088327A1/es active IP Right Grant
-
2014
- 2014-04-01 IL IL231856A patent/IL231856A/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02556A patent/ZA201402556B/en unknown
- 2014-04-09 DO DO2014000070A patent/DOP2014000070A/es unknown
- 2014-04-10 GT GT201400064A patent/GT201400064A/es unknown
- 2014-04-10 CL CL2014000905A patent/CL2014000905A1/es unknown
- 2014-05-06 CR CR20140205A patent/CR20140205A/es unknown
- 2014-05-07 CO CO14097093A patent/CO6950476A2/es unknown
- 2014-05-08 EC ECIEPI2014357A patent/ECSP14000357A/es unknown
-
2015
- 2015-06-30 PH PH12015501498A patent/PH12015501498B1/en unknown
-
2016
- 2016-10-27 CY CY20161101096T patent/CY1118224T1/el unknown
-
2017
- 2017-04-19 JP JP2017082912A patent/JP6395893B2/ja active Active
- 2017-07-20 AU AU2017206246A patent/AU2017206246B2/en not_active Ceased
-
2019
- 2019-02-01 DO DO2019000022A patent/DOP2019000022A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11786519B2 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| AU2017206246B2 (en) | 8 - carbamoyl - 2 - (2 , 3 - disubstituted pyrid - 6 - yl) -1 , 2 , 3 , 4 - tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| TWI634118B (zh) | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘導劑 | |
| ES2699966T3 (es) | Agentes inductores de la apoptosis para el tratamiento del cáncer y enfermedades inmunes y autoinmunes | |
| NZ623100B2 (en) | 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| HK1200167B (en) | 8-carbamoyl-2-(2,3-disubstituted pyrid-6-yl)-1,2,3,4-tetrahydroisoquinoline derivatives as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| NZ623068B2 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/10/2012, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2849 DE 12-08-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |